Rachel Meyers

Chief Science Officer, Faze Medicines

Dr. Rachel Meyers currently serves as the Chief Scientific Officer at Faze Medicines, a recently launched and well-funded biotechnology company focused on the regulation of biomolecular condensates to treat disease. She was most recently an entrepreneur-in-residence at Third Rock Ventures (TRV), where she helped drive the creation of Faze Medicines. Prior to joining TRV, Rachel was a consultant, advising a number of biotech companies and venture capital firms and currently serves on a number of Scientific Advisory Boards. She joined TRV from Alnylam Pharmaceuticals (2003 – 2017), where she was most recently Senior Vice President of Research and RNAi Lead Development. In this capacity, she played a key role in advancing RNAi therapeutic programs from early discovery through clinical development, and her team was responsible for program leadership for most of the company’s preclinical and clinical stage programs. Rachel also had overall responsibility for the chemistry and platform technology efforts that are the underpinnings of the company’s pipeline. She was the project lead for the company’s RSV program, where she was responsible for leading ALN-RSV01, the companies first clinical program, from inception, through preclinical and clinical development. In 2007, Rachel was honored by Mass High Tech as one of 10 Women to Watch and by R&D Directions as one of its Top 20 Scientists. Before joining Alnylam in 2003, Rachel was a senior scientist at Millennium Pharmaceuticals (1999 – 2003) where she led a unit of the company’s target discovery and validation efforts involving bioinformatics and molecular and cell biology.  Dr. Meyers completed her postdoctoral training with Dr. Lewis Cantley, at Harvard Medical School, in the field of signal transduction, and received her PhD at MIT working with Nobel Laureate Dr. Phil Sharp, in the field of in vitro transcription.